Comparing TransEnterix (OTCMKTS:TRXDW) & Biosig Technologies (NASDAQ:STEX)

Biosig Technologies (NASDAQ:STEX) and TransEnterix (OTCMKTS:TRXDW) are both small-cap manufacturing companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for Biosig Technologies and TransEnterix, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1	0	0	0	1.00
TransEnterix	0	0	0	0	0.00

Profitability

This table compares Biosig Technologies and TransEnterix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	N/A	-64.96%
TransEnterix	-2,149.15%	-83.74%	-64.94%

Risk & Volatility

Biosig Technologies has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Comparatively, TransEnterix has a beta of 2.56, suggesting that its stock price is 156% more volatile than the S&P 500.

Institutional and Insider Ownership

7.2% of Biosig Technologies shares are owned by institutional investors. Comparatively, 8.2% of TransEnterix shares are owned by institutional investors. 52.7% of Biosig Technologies shares are owned by company insiders. Comparatively, 3.1% of TransEnterix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Biosig Technologies and TransEnterix”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$40,000.00	12,488.70	-$10.33 million	($1.35)	-2.32
TransEnterix	$8.53 million	2.51	-$154.20 million	($4.22)	-0.04

Biosig Technologies has higher earnings, but lower revenue than TransEnterix. Biosig Technologies is trading at a lower price-to-earnings ratio than TransEnterix, indicating that it is currently the more affordable of the two stocks.

Summary

Biosig Technologies beats TransEnterix on 7 of the 11 factors compared between the two stocks.

About Biosig Technologies

BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company’s proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.

About TransEnterix

TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. TransEnterix, Inc. is headquartered in Morrisville, North Carolina.